Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Overcoming Chemotherapy Resistance in SCLC
Brett H. Herzog, Siddhartha Devarakonda, Ramaswamy Govindan
Journal of Thoracic Oncology (2021) Vol. 16, Iss. 12, pp. 2002-2015
Open Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Bilan Wang, Shiqi Hu, Yan Teng, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 93
Traditional Chinese Medicine has great potential as candidate drugs for lung cancer: A review
Zhicheng Wei, Jing Chen, Fang Zuo, et al.
Journal of Ethnopharmacology (2022) Vol. 300, pp. 115748-115748
Closed Access | Times Cited: 82
Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance
Adnin Ashrafi, Zakia Akter, Pouya Modareszadeh, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4562-4562
Open Access | Times Cited: 75
Novel strategies for cancer immunotherapy: counter-immunoediting therapy
Shaochuan Liu, Qian Sun, Xiubao Ren
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 50
The CDK inhibitor AT7519 inhibits human glioblastoma cell growth by inducing apoptosis, pyroptosis and cell cycle arrest
Wenpeng Zhao, Liang Zhang, Yaya Zhang, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 46
The role of stem cells in small-cell lung cancer: Evidence from chemoresistance to immunotherapy
Wenwen Guo, Tianyun Qiao, Tian Li
Seminars in Cancer Biology (2022) Vol. 87, pp. 160-169
Open Access | Times Cited: 60
Silicon switch: Carbon–silicon Bioisosteric replacement as a strategy to modulate the selectivity, physicochemical, and drug‐like properties in anticancer pharmacophores
Jean Fotie, Caitlyn M. Matherne, Jordan E. Wroblewski
Chemical Biology & Drug Design (2023) Vol. 102, Iss. 2, pp. 235-254
Closed Access | Times Cited: 31
The application of patient-derived organoid in the research of lung cancer
Yin Li, Xinyu Gao, Chao Ni, et al.
Cellular Oncology (2023) Vol. 46, Iss. 3, pp. 503-519
Open Access | Times Cited: 26
Recent Advances in the Clinical Translation of Small-Cell Lung Cancer Therapeutics
Subhadeep Das, Shayak Samaddar
Cancers (2025) Vol. 17, Iss. 2, pp. 255-255
Open Access | Times Cited: 1
Differential expression of the MYC‐Notch axis drives divergent responses to the front‐line therapy in central and peripheral extensive‐stage small‐cell lung cancer
Libo Luo, Rui Xia, Shiqi Mao, et al.
MedComm (2025) Vol. 6, Iss. 3
Open Access | Times Cited: 1
Tumor-associated macrophages in non-small-cell lung cancer: From treatment resistance mechanisms to therapeutic targets
Zhenjun Huang, Ziqi Xiao, Li‐Qing Yu, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 196, pp. 104284-104284
Open Access | Times Cited: 7
Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer
Marcello Stanzione, Jun Zhong, Edmond Wong, et al.
Science Advances (2022) Vol. 8, Iss. 19
Open Access | Times Cited: 24
Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma
Cong Liu, Dingwei Liu, Fangfei Wang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 23
Inducing ferroptosis by traditional medicines: a novel approach to reverse chemoresistance in lung cancer
Yumin Wang, Jing Hu, Joshua S. Fleishman, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations
Ildikó Krencz, Dániel Sztankovics, Titanilla Dankó, et al.
Cancer and Metastasis Reviews (2021) Vol. 40, Iss. 4, pp. 1141-1157
Open Access | Times Cited: 30
A CT-based radiomics nomogram for predicting the progression-free survival in small cell lung cancer: a multicenter cohort study
Xiaomin Zheng, Kai‐Cai Liu, Cuiping Li, et al.
La radiologia medica (2023) Vol. 128, Iss. 11, pp. 1386-1397
Closed Access | Times Cited: 13
Cell-free and extrachromosomal DNA profiling of small cell lung cancer
Roya Behrouzi, Alexandra Clipson, Kathryn Simpson, et al.
Trends in Molecular Medicine (2024)
Open Access | Times Cited: 4
Accurate delivery of pristimerin and paclitaxel by folic acid-linked nano-micelles for enhancing chemosensitivity in cancer therapy
Chao Chen, Shiyu Du, Wu Zhong, et al.
Nano Convergence (2022) Vol. 9, Iss. 1
Open Access | Times Cited: 18
FOXA1 activates NOLC1 transcription through NOTCH pathway to promote cell stemness in lung adenocarcinoma
Jifa Li, Xiaoqiong Bao, Wenwen Yu, et al.
The Kaohsiung Journal of Medical Sciences (2025)
Open Access
Preclinical evidence that fibroblast growth factor receptor pathway inhibition by BGJ398 enhances small cell lung cancer response to chemotherapy
Yingying Shen, Yan Jiang, Junyao Wu, et al.
Anti-Cancer Drugs (2025)
Closed Access
Long-term course of disease in 71-year-old patient with diagnosis of small cell lung cancer – case report and literature review
Piotr Kalisz, Bartłomiej Gałuszka, Sabina Kostorz‐Nosal, et al.
Annales Academiae Medicae Silesiensis (2025) Vol. 79, pp. 36-44
Open Access
Discovery and Antitumor Evaluation of a Mitochondria-Targeting Ruthenium Complex for Effective Cancer Therapy
Peng Liu, Shangbo Zhou, Zhijun Zhou, et al.
Cancer Letters (2025) Vol. 616, pp. 217582-217582
Open Access
ACT001 Suppresses the Malignant Progression of Small‐Cell Lung Cancer by Inhibiting Lactate Production and Promoting Anti‐Tumor Immunity
Xin Ding, Ting Mei, Xiaonan Xi, et al.
Thoracic Cancer (2025) Vol. 16, Iss. 5
Open Access
A Recurrent Small Cell Lung Carcinoma Harboring an EML4–ALK Fusion Mutation with Sustained Response to Ensartinib: A Case Report
Hao Jiang, Tengfei Zhu, Zenghao Chang, et al.
Current Oncology (2025) Vol. 32, Iss. 3, pp. 163-163
Open Access
Targeting FOXP1 phase separation in small cell lung cancer mechanisms of chemotherapy resistance
Yichun Tang, Yuchun Niu, Yi Chen, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top